AAAhmad Amanzada

Ahmad Amanzada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ahmad Amanzada has a total of 100 co-authors. Here are the top co-authors by number of shared publications:

  • Volker Ellenrieder

    Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Germany

    11 shared publications
  • Steffen Kunsch

    Department of General Internal Medicine and Gastroenterology, Rems-Murr-Klinikum Winnenden, Winnenden, Germany

    9 shared publications
  • Nicolae-Catalin Mechie

    Clinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology

    7 shared publications
  • Eirini Mavropoulou

    Clinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology

    6 shared publications
  • Golo Petzold

    Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Gottingen, Germany

    6 shared publications
  • Ahmed Abd El Wahed

    Institute of Animal Hygiene and Veterinary Public Health, Leipzig University

    4 shared publications

Latest Publications

  • Open Access

    A dataset on the phylogeny of Mycobacterium avium subsp. paratuberculosis isolated from patients in a referral gastrointestinal diseases centre in the Sudan

    by Sanaa M. Idris, Wisal A. Elmagzoub, Maha Isameldin, Nassir Arabi, Abdelmonem Abdo, Mustafa Ibrahim, Sahar M. Bakhiet, Julius B. Okuni, Lonzy Ojok, Ahmed A. Gameel, et al.


  • Open Access

    Prevalence and molecular insights of Mycobacterium avium subsp. paratuberculosis in Sudanese Cattle: implications for control and public health

    by Sanaa M. Idris, Wisal A. Elmagzoub, Mohamed E. Mukhtar, Julius B. Okuni, Lonzy Ojok, Enass M. Abdalla, Sulieman M. El Sanousi, Ahmad Amanzada, Uwe Truyen, Ahmed Abd El Wahed, et al.

    Paratuberculosis (PTB) is a chronic intestinal disease affecting ruminants and somenon-ruminants, caused by Mycobacterium avium subsp. paratuberculosis (MAP). In the Sudan, published data on the incidence and prevalence of PTB are Limited. we detected MAP in human patients with gastrointestinal complaints highlights its zoonotic potential and raises public health concerns. This study aimed at assessing PTB prevalence in cattle and identifying risk factors for MAP infection as well as investigating the phylogeny of MAP circulating in the Sudan. Both serum and faecal samples were collected from the same individual animals of 810 cattle in 153 herds in five states spanning three regions (Southern, Northern, and Central) of the country. ELISA was used to detect MAP antibodies in sera, while faecal samples were tested for MAP DNA using a recombinase aided amplification (RAA) assay and cultured for MAP isolation followed by partial sequencing of MAP insertion sequence 1311 with subsequent phylogeny analysis. At the animal level, the apparent prevalence was 5.0% for ELISA and 4.2% for RAA, with true prevalence estimates of 8.5% and 4.8%, respectively. At the herd level, apparent prevalence was 28.2% for ELISA and 22.3% for RAA, while true prevalence reached 54.2% for ELISA and 24.9% for RAA. Significant ( P < 0.05) risk factors for MAP infection included exposure to wild animals and high rainfall. Phylogenetic analysis of the Sudanese MAP isolates revealed close relatedness to type S (I/III) strains worldwide suggesting a shared evolutionary origin. The present study provides baseline data on PTB prevalence and risk factors in Sudanese cattle, emphasising the role of environmental and management factors in disease dynamics. These findings highlight the necessity of adopting targeted control strategies to reduce MAP impact on cattle and other animals as well as to prevent its potential public health hazard.


  • Open Access

    Endoscopic submucosal dissection with a novel cap-assisted additional working channel (AWC duo) increases resection speed: a pilot study

    by Steffen Kunsch, Christoph Ammer-Herrmenau, Abdelghani Nedjahi, Richard F Knoop, Volker Ellenrieder, Ahmad Amanzada, Albrecht Neesse

    Objective The additional working channel duo (AWC duo) is a novel ‘bi-manual’ tool to perform endoscopic submucosal dissection (ESD) combining an AWC with a transparent spacer cap to facilitate ESD procedures. In this study, we investigate the resection speed, safety and feasibility of AWC duo ex vivo and in patients. Methods and design In an ex vivo porcine stomach model, n=15 resections on 4 cm lesions were performed using the AWC duo ESD or conventional cap-assisted ESD. Resection time, en-bloc rate and feasibility were analysed. Data of n=22 patients that had undergone AWC duo assisted ESDs were retrospectively evaluated. Result Ex vivo, dissection time was significantly shorter in the AWC duo group compared with standard cap-assisted ESD (17 min vs 21 min, pConclusion AWC duo reveals a significant reduction of dissection time compared with standard cap-assisted ESD in the porcine ex vivo model. First patient data highlight the safety and practicability of AWC duo as a novel and promising tool to facilitate ESD resections in the upper and lower gastrointestinal tract.

  • Open Access

    Successful delayed endoscopic management of dislocated hepaticogastrostomy stent with self-expanding metal stent and esophageal perforation closure

    by André Sasse, Benjamin Christian Steuber, Volker Ellenrieder, Golo Petzold, Thomas Roland Heiduk, Ahmad Amanzada

    Endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) is an emerging procedure for relieving malignant jaundice especially in palliative situations. Complications such as stent dislocation are relatively rare (3%) and are typically managed surgically [1] [2] [3]. There are only a few case reports of endoscopic solutions for dislocated EUS-HGS stents [4]. We present the case of a woman who was transferred to our university medical center for surgery due to a dislocated metal stent following EUS-HGS. Initially, the patient presented with painless jaundice ([Fig. 1]) and underwent endoscopic retrograde cholangiopancreatography (ERCP), which revealed a possibly malignant subhilar stenosis of the biliary tract. A plastic stent was placed, but the serum bilirubin level did not decrease and cholestasis persisted. The patient refused surgery and further diagnostics but agreed to undergo EUS-HGS to relieve her obstructive jaundice. After placement of the metal stent, it dislocated into the peritoneum, resulting in peritoneal bile leakage, perforation of the distal esophagus due to misplacement of the EUS-HGS stent, and pneumoperitoneum ([Fig. 2]). After careful interdisciplinary discussion, we performed endoscopic interventions under general anesthesia ([Video 1]). The gastroscopy revealed a large perforation ([Fig. 3]). The metal stent was endoscopically removed from the peritoneal cavity through the perforation using additional fluoroscopic guidance, a thin gastroscope, underwater endoscopy, and alligator grasping forceps to retrieve the metal stent ([Fig. 4]). Subsequently, the perforation was successfully closed with through-the-scope-clips. A new EUS-HGS with a semi-covered metal stent was then performed to ensure adequate bile drainage ([Fig. 5]). Gastroscopic follow-up confirmed proper closure of the esophageal perforation, correct placement of the metal stent, and sufficient bile drainage. The patient was extubated after the procedure and recovered well. Serum bilirubin levels decreased significantly and rapidly. This case demonstrates that dislocation of an EUS-guided drain into the peritoneal cavity with perforation of the gastrointestinal wall can be successfully treated endoscopically. Endoscopy_UCTN_Code_CPL_1AL_2AD Article published online: 09 April 2025 © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

  • Open Access

    Enhancing emergency endoscopy efficiency with an additional suction channel: In vitro assessment

    by André Sasse, Thomas Roland Heiduk, Marvin Scheunemann, Lukas Hiebel, Richard F Knoop, Marius Adler, Ali Seif Amir Hosseini, Edris Wedi, Imke Amanzada, Volker Ellenrieder, et al.

    Emergency endoscopic interventions for upper gastrointestinal hemorrhage are frequently hampered by presence of blood clots and food debris. This study aimed to assess whether integration of an additional suction channel (ASC) onto a standard gastroscope enhances efficiency of aspirating clots and viscous fluids. A 5.3-mm suction catheter was used as an ASC mounted on a 2.8-mm standard gastroscope. Suction efficacy was evaluated using gastroscopes with working channel diameters of 2.8 mm, 3.7 mm, and 6 mm in vitro. Defined volumes of water, fruit yogurt, and coagulated blood were aspirated, and time required for complete evacuation was measured. Each setup was tested with and without the BioVac system. The ASC significantly enhanced suction performance across all test media. Notably, the 2.8-mm gastroscope with ASC outperformed all other configurations in aspirating water and yogurt. For clotted blood, the ASC significantly improved evacuation times compared with all other setups besides 6-mm + BioVac. A standard gastroscope equipped with an ASC significantly enhances suction performance in an in vitro model, outperforming gastroscopes with larger working channels. These findings warrant further validation in an ex vivo model to determine their clinical applicability.

  • Open Access

    Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis

    by Sebastian C. B. Bremer, Gabi Bittner, Omar Elakad, Helen Dinter, Jochen Gaedcke, Alexander O. König, Ahmad Amanzada, Volker Ellenrieder, Alexander Freiherr von Hammerstein-Equord, Philipp Ströbel, et al.

    Tumor grading is a robust prognostic predictor in patients with neuroendocrine neoplasms (NEN) and guides therapy, especially in tumors with high proliferation. NEN can be separated into well-differentiated and poorly differentiated types. The more aggressive NEN have been further separated into neuroendocrine tumors (NET G3) with a better prognosis and neuroendocrine carcinomas (NEC) with a worse prognosis. Despite this distinction’s tremendous clinical and therapeutic relevance, optimal diagnostic biomarkers are still lacking. In this study, we analyzed the protein expression and prognostic impact of Enhancer of Zeste Homolog 2 (EZH2) by immunohistochemistry in 219 tissue samples of gastroenteropancreatic (GEP-NEN) and pulmonary NEN (P-NEN). EZH2 was almost exclusively expressed in NEN with a proliferation rate above 20% (G3), while all low-grade tumors were nearly negative. Among high-grade NEN, 65% showed high and 35% low expression of EZH2. In this group, the high expression of EZH2 was significantly associated with poor overall survival and NEC histology. Interestingly, EZH2 seems to act independently of Polycomb Repressive Complex 2 (PRC2) in NEN. In conclusion, we propose EZH2 as a robust biomarker for distinguishing between NET G3 and NEC among gastroenteropancreatic and pulmonary NEN.


  • Open Access

    Induction of remission with tacrolimus in a patient with severe acute, cortisone refractory ulcerative colitis and severe Covid-19 pneumonia: a case report

    by Lisanne Rieker, Johannes Hofer, Golo Petzold, Volker Ellenrieder, Ahmad Amanzada

    Background: Therapy regimens used in patients with inflammatory Bowel Disease (IBD) have been associated with enhanced risk of viral infections or viral reactivation. Moreover, it is uncertain whether IBD patients have increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or infected patients may have an increased risk for severe coronavirus disease 2019 (Covid-19). Managing severe acute flare in ulcerative colitis during the Covid-19 pandemic is a challenge for clinicians and their patients. The results of the published studies mainly report on the role of the prior medication, but not how to treat severe acute flare of IBD patients with severe Covid-19 pneumonia. Case presentation: We report the case of a 68-year-old patient with a long history of ulcerative colitis. He was initially admitted to an external hospital because of severe acute flare. The initiation of a high-dose oral cortisone therapy did not improve the clinical symptoms. During the inpatient treatment, he was tested positive for SARS-CoV-2. At admission to our hospital the patient showed severe flare of his ulcerative colitis and increased Covid-19 symptoms. A cortisone-refractory course was noticed. After detailed multidisciplinary risk–benefit assessment, we initiated an intravenous tacrolimus therapy and dose of prednisolone was tapered gradually. After clinical response, the therapy was adjusted to infliximab. Additionally, the Covid-19 pneumonia was kept under control despite immunosuppression and the patient could be discharged in clinical remission. Conclusions: This case suggest the use of tacrolimus as a bridging therapeutic option for severe acute, cortisone refractory ulcerative colitis in Covid-19 patients. Nevertheless, the best treatment strategy for IBD patients presenting a flare during the outbreak has yet to be defined. Further data for IBD patients under calcineurin inhibitor therapy are urgently needed.


  • Open Access

    Mycobacterium avium subsp. paratuberculosis Virulence: A Review

    by Judah Ssekitoleko, Lonzy Ojok, Ahmed Abd El Wahed, Joseph Erume, Ahmad Amanzada, ElSagad Eltayeb, Kamal H. Eltom, Julius Boniface Okuni

    To propose a solution for control of Mycobacterium avium subsp. paratuberculosis (MAP) infections in animals as well as in humans, and develop effective prevention, diagnostic and treatment strategies, it is essential to understand the molecular mechanisms of MAP pathogenesis. In the present review, we discuss the mechanisms utilised by MAP to overcome the host defense system to achieve the virulence status. Putative MAP virulence genes are mentioned and their probable roles in view of other mycobacteria are discussed. This review provides information on MAP strain diversity, putative MAP virulence factors and highlights the knowledge gaps regarding MAP virulence mechanisms that may be important in control and prevention of paratuberculosis.


  • Open Access

    Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn disease patients

    by Nicolae-Catalin Mechie, Merle Burmester, Eirini Mavropoulou, Yiannis Pilavakis, Steffen Kunsch, Volker Ellenrieder, Ahmad Amanzada

    Ustekinumab (UST) is approved for the treatment of moderate and severe Crohn disease (CD). Therapeutic drug monitoring (TDM) can help monitor the therapeutic effects of biologics. Therefore, the aim of this study was to evaluate the clinical outcomes of UST-treated CD patients and to determine the UST trough level in clinical and corticosteroid-free remission. This retrospective study included patients with moderate and severe active disease (AD) treated intravenously with a weight-adapted induction dose of UST. The maintenance therapy consisted of 90 mg UST subcutaneously at week 8 and thereafter every 8 or 12 weeks, depending on the clinical response. Clinical and corticosteroid-free remission, Harvey-Bradshaw-Index (HBI), UST trough level, and further laboratory parameters were measured just before the injection of UST at each follow-up evaluation until week 40. 37 CD patients with a median HBI of 9 at week 0 were included in the study. Starting from 24% at the beginning of the monitoring period, and 38% of patients at the end of the monitoring period were treated with an 8-week interval (P = .18). There was a significant improvement in clinical (P = .0004), corticosteroid-free remission (P = .03), and HBI (P < .0001) from week 0 until the end of the observation period. The serum UST trough level decreased significantly from 2.0 at week 8 to 0.3, in the maintenance therapy and 0.4 μg/ml at the end of the therapy (P < .0001). Neither UST trough level nor levels of C-reactive protein (CRP) or fecal calprotectin (FC) were associated with disease outcome. Concomitant immunomodulator therapy did not appear to affect the UST trough level or clinical course. UST is an effective treatment option for difficult-to-treat patients with CD. UST trough levels may not be associated with treatment efficacy or the prediction of treatment outcomes in patients with CD. Further prospective randomized trials should be conducted to evaluate whether UST trough levels are associated with treatment outcomes in patients with CD.


  • Open Access

    Evaluation of ustekinumab trough levels during induction and maintenance therapy with regard to disease activity status in difficult to treat Crohn Disease patients

    by Nicolae-Catalin Mechie, Merle Burmester, Eirini Mavropoulou, Yiannis Pilavakis, Steffen Kunsch, Volker Ellenrieder, Ahmad Amanzada

    Background Ustekinumab (UST) is approved for the therapy of moderate and severe Crohn disease (CD). Therapeutic drug monitoring (TDM) helps to monitor the therapeutic effect of biologics. Therefore, the aim of this study was to evaluate clinical outcomes of UST treated CD patients and to determine UST trough level (USTTL) with clinical and corticosteroid-free remission.Methods This retrospective study of CD included patients with moderate and severe active disease treated with a weight adapted induction dose of UST intravenously. The maintenance therapy consisted of 90 mg UST subcutaneously at week 8 and thereafter every 8 or 12 weeks depending on the clinical response. Clinical and corticosteroid-free remission, Harvey-Bradshaw-Index (HBI), USTTL and further laboratory parameters were measured just before the injection of UST at each follow-up evaluation until week 40.Results 37CD patients with a median HBI of 9 at week 0 were included. Starting from 24% at the beginning of the monitoring period and 38% of patients at the end of it, were treated with an 8-week interval (p = 0.18). There was a significant improvement of clinical (p = 0.0004) and corticosteroid-free remission (p = 0.03) as well as in HBI (p < 0.0001) from week 0 until the end of the observation period, respectively.The serum USTTL decreased significantly from 2.0 at week 8 to 0.3 in the maintenance therapy and 0.4 µg/mL at the end of it (p < 0.0001), respectively. Neither USTTL nor levels of CRP or faecal calprotectin were associated with disease outcome. Concomitant immunomodulator therapy did not appear to affect the USTTL or the clinical course.Conclusions UST is an effective treatment option in difficult to treat CD patients. USTTL may not be associated with treatment efficacy or predict treatment outcomes in CD patients. Further prospective randomized trials should be conducted to evaluate if USTTL is associated with treatment outcomes in CD patients.